Houston, TX -- (ReleaseWire) -- 04/26/2017 -- AngioSoma, Inc., (OTCMKTS:SOAN) recently filed its 10K for the period ending September 30, 2016 and its 10Q for the period ending December 31, 2016. AngioSoma, Inc.'s management would like to update its shareholders on recent progress within its 2017 business plan, including starting operations at its SOMA Nutraceuticals, Inc. subsidiary and retaining Boustead Securities LLC.

After receiving intellectual property in November 2016, SOMA Nutraceuticals, Inc. began operations in March 2017 by retaining a team including Dale R. Greenwald, C.S.C.S. as its president and David P. "Doc" Summers PhD as a consultant working on further research.  Mr. Greenwald is a nationally recognized lecturer in the field of Exercise Physiology and Sports Medicine and an internationally recognized author in the field of exercise for his book "Weight Training by Design: Customize Your Own Fitness and Weight Loss Program Using the Revolutionary BAM Superset System".

Boustead Securities LLC ("Boustead") was retained in February 2017 as a "Placement Agent" and to provide "Advisory Services" for the Company's AngioSoma Research, Inc. subsidiary.  Management is currently working with Boustead to secure funding for SOMA Nutraceuticals, Inc. operations including intellectual property extension and oversight, and shareholder communications.  "We are excited to be leveraging the strength and experience of Boustead Securities as Placement Agent as we begin implementing our 2017 business plan" said AngioSoma, Inc.'s CEO Alex K. Blankenship.

Keith Moore, CEO of Boustead Securities, said that "We are looking forward to working with Alex and her team at AngioSoma as they launch strategic intellectual property monetization strategies."

The Company's management was not able to complete an agreement to bring on Ken Stephenson as its new CEO in December 2016, so Ms. Blankenship continues as its CEO and President.  Also, the Company announced a forward split to be effective January 6, 2017 but management decided that it was not in the best interests of its shareholders to do so at that time and did not complete that forward split.

Please note the Company's new phone number of 832-263-2665 and headquarters' address of 2500 Wilcrest Drive, Third Floor, Houston, Texas 77042.

About AngioSoma, INC.
AngioSoma, Inc. (http://angiosoma.info) is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments related to pharmaceutical or endovascular interventions. Our "end to end" solution will provide interventional radiologists, cardiologists, and internal medicine physicians with both pharmaceutical and or endovascular interventional options prior to infarction or critical limb ischemic events, stabilizing or reversing the atherosclerotic disease.

Our Soma Nutraceutical Inc. subsidiary aims to provide dietary anti-inflammatory, blood thinning, and anti-clotting natural products, as either stand alone or adjuncts to pharmaceutical care.

For pharmaceutical stabilization, our Liprostin™ product for treatment of peripheral artery disease ("PAD") completed preliminary U.S. Food and Drug Administration ("FDA") required Phase I and Phase II clinical trials successfully and is entering Phase III prior to approval. Our AngioSoma Research, Inc. subsidiary also owns the OmniCath I & II plaque debulking and vessel remodeling atherectomy catheter which will further support the stabilization of patients experiencing infarction or critical limb ischemic symptoms.

For long-term preventative measures, our Transdermal PGE-1 Patch will provide ongoing treatment for chronic cardiovascular disease by delivery of PGE-1 or Liprostin™ through the skin.

In all, we have a robust product pipeline from 20+ years of research and development, with existing patents, provisional patents, formulations, and trademarks from previously successful products.

About Boustead Securities, LLC
Boustead Securities, LLC is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead's core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services.

For more information, visit www.boustead1828.com.

NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

CONTACT:
AngioSoma, Inc.
Alex Blankenship
investors@angiosoma.info | info@angiosoma.info
832-263-2665

Boustead Securities, LLC:
Keith Moore, CEO
949-295-1580
keith@boustead1828.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/angiosoma-inc-starts-soma-nutraceuticals-incs-operations-799411.htm

Montgomery, TX -- (ReleaseWire) -- 01/19/2017 -- AngioSoma, Inc., (OTCQB:SOAN) today announced Kenneth Stevenson, who previously had agreed to accept the position of President and Chief Executive Officer (CEO) has since withdrawn from his agreement and resigned all positions. This was a mutual decision and the company wishes him the best of luck. Additionally, the shareholder dividend which was erroneously stated as "forward stock split" announced on December 21, 2016, to become effective on January 16, 2017, has been indefinitely postponed. The company's management feels that any change in the total and outstanding shares might be disadvantageous to the company's shareholders now.

The company's previously announced joint venture partner, La Jolla Capital Partners, LLC are working closely with us to close its search for a "big Pharma" partner who can assist in the introduction of Liprostin™, the company's signature pharmaceutical for treatment of peripheral artery disease (PAD).

For pharmaceutical stabilization of PAD, Liprostin™ our liposomal encapsulated prostaglandin e1 (PGE1) product for treatment of peripheral artery disease ("PAD") completed preliminary U.S. Food and Drug Administration ("FDA") required Phase I and Phase II clinical trials successfully and is entering Phase III for final market approval. Our AngioSoma Research, Inc. subsidiary also owns the OmniCath™I & II plaque debulking and vessel remodeling atherectomy catheter with our PGE1 coated vascular stents which will further support the stabilization of patients experiencing coronary artery ischemia or critical limb ischemic symptoms.

For long-term preventative measures, our Transdermal PGE-1 Patch will provide ongoing treatment for chronic cardiovascular disease by delivery of PGE-1 or Liprostin™ through the skin. In all, we have a robust product pipeline from 20+ years of research and development, with 20 existing patents, newly filed patents, drug formulations, and trademarks based on the "prior art" of previously successful patents and products.

Finally, the company is pleased to announce the appointment of Dale Greenwald as President of our new subsidiary, Soma Nutraceuticals, Inc. Dale is a certified exercise physiologist who works closely with the University of Colorado, Boulder. "Soma" has an array of all-natural dietary products which aims to provide all-natural early anti-inflammatory, blood thinning, and anti-clotting dietary supplements, as either stand alone or adjuncts to pharmaceutical care alongside its fitness and anti-aging supplements.

NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success is no guarantee of success.

This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

CONTACT:
AngioSoma, Inc.
Alex Blankenship
832-781–8521
www.investors@angiosoma.info | info@angiosoma.info

For more information on this press release visit: http://www.releasewire.com/press-releases/angiosomas-president-and-ceo-kenneth-stevenson-resigns-from-position-761711.htm